Načítá se...
Driving an improved CAR for cancer immunotherapy
The recent clinical success of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies represents a paradigm shift in cancer immunotherapy. Unfortunately, application of CAR T cell–mediated therapy for solid tumors has so far been disappointing, and the reasons for this poor response...
Uloženo v:
| Vydáno v: | J Clin Invest |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society for Clinical Investigation
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4966332/ https://ncbi.nlm.nih.gov/pubmed/27454296 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI88959 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|